Rhythm Pharmaceuticals, Inc.
RYTM
$115.48
-$0.54-0.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 53.51% | 58.67% | 45.83% | 54.92% | 53.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.51% | 58.67% | 45.83% | 54.92% | 53.55% |
| Cost of Revenue | 57.02% | 61.86% | 45.80% | 44.18% | 47.43% |
| Gross Profit | 53.09% | 58.30% | 45.83% | 56.30% | 54.32% |
| SG&A Expenses | 51.98% | 47.27% | 35.09% | 26.74% | 18.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.01% | 33.94% | 25.90% | 26.22% | 21.37% |
| Operating Income | -13.07% | -14.34% | -10.92% | -7.56% | -2.46% |
| Income Before Tax | -11.58% | -19.67% | 24.66% | 25.70% | 29.06% |
| Income Tax Expenses | 6,388.24% | 669.60% | 44.06% | -30.59% | -101.27% |
| Earnings from Continuing Operations | -12.17% | -20.15% | 24.57% | 25.72% | 29.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.17% | -20.15% | 24.57% | 25.72% | 29.44% |
| EBIT | -13.07% | -14.34% | -10.92% | -7.56% | -2.46% |
| EBITDA | -13.44% | -14.66% | -11.16% | -7.72% | -2.55% |
| EPS Basic | -3.31% | -11.46% | 28.70% | 28.47% | 30.88% |
| Normalized Basic EPS | -3.31% | -5.98% | -4.12% | -4.06% | -0.03% |
| EPS Diluted | -3.31% | -11.46% | 28.70% | 28.47% | 30.88% |
| Normalized Diluted EPS | -3.31% | -5.98% | -4.12% | -4.06% | -0.03% |
| Average Basic Shares Outstanding | 8.07% | 7.25% | 6.52% | 5.39% | 4.75% |
| Average Diluted Shares Outstanding | 8.07% | 7.25% | 6.52% | 5.39% | 4.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |